James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.
Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification and the implications for treatment with immune checkpoint blockade (Abstract 47).
Ann W. Silk, MD, of the Rutgers Cancer Institute of New Jersey, and Katy K. Tsai, MD, of the University of California, San Francisco, who are Co-Chairs of the Clinical Immuno-Oncology Symposium, discuss highlights of the meeting and progress in the field.
Roy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents, overcoming resistance, and using treatment combinations.
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.
Kristen Fousek, PhD Candidate at Baylor College of Medicine, discusses her preclinical work on targeting CD19-negative relapsed B-cell acute lymphoblastic leukemia, using CAR T cells that target three antigens simultaneously, a technique that addresses the growing problem of relapse (Abstract 121).
